Targeting with PD-1, PD-L1, or CTLA-4 reverses the enervation of cytotoxic T lymphocytes, thereby leading to tumor cell elimination via the induction of the normal functioning of T cells. The gene discussed is PDCD1; the disease is neoplasm.